
ãã¡ã€ã¶ãŒã²ãŒã:ã³ãã19ã¯ã¯ãã³æ¥çš®ãåŸå€©æ§å ç«äžå šçå矀ãåŒãèµ·ãã
å èšäºã¯ãã¡ã/Original article here
圌ãã¯ãã«ãŒããå¹³ãã«ããã®ã«3é±éå¿
èŠã ãšèšã£ãã
圌ãã¯åãã€ããŸããã
å®¶ã«ããã°å»çãµãŒãã¹ãå®ãããšèšã£ãã
圌ãã¯åãã€ããŸããã(ãœãŒã¹)
圌ãã¯ãäžçäžã®äœçŸäžäººãã®äººã
ãCovid-19ã§æ»ãã§ãããšèšã£ãã
圌ãã¯åãã€ããŸããã(æ
å ±æº)
圌ãã¯ãã³ããã»ã¯ã¯ãã³ãæ¥çš®ããã°ãã³ãã19ã«ææããªããšèšããŸããã
圌ãã¯åãã€ããŸããã(åºå
ž)
ãããããããªãã¯ãCovidã¯ã¯ãã³ãæ¥çš®ãããšãCovid-19ã«ææããããCovid-19ãäŒæãããããå¯èœæ§ãäœããªããšèšãããŸããã
圌ãã¯åãã€ããŸããã(åºå
ž)
圌ãã¯ãCovidã¯ã¯ãã³ã¯å®å
šã§å¹æçã§ãããšããªãã«äŒããŸããã
圌ãã¯åãã€ããŸããã(åºå
ž)
圌ãã¯ãCovidã¯ã¯ãã³ã®å
容ç©ã¯æ³šå°éšäœã«çãŸããšèšããŸããã
圌ãã¯åãã€ããŸããã(åºå
ž)
圌ãã¯ãmRNAã³ããã-19ã¯ã¯ãã³ã¯ãããªãã®DNAã«å¹²æžããªããšèšããŸããã
圌ãã¯åãã€ããŸããã(åºå
ž)
ä»ã圌ãã¯ãCovid-19ã¯ã¯ãã³ã¯æéãçµã€ãšå¹æããªããªãã®ã§ãç¹°ãè¿ãããŒã¹ã¿ãŒã·ã§ãããå¿ èŠã ãšäŒããããšããŠããŸãã
ãããã圌ãã¯ãŸãããŠãåãã€ããŠãããã³ããã-19ã¯ã¯ãã³ã¯å¹æã倱ããªããããã©ããããç§ãã¡ã¯ã³ããã-19泚å°ã2å以äžåãã人ã®ã»ãšãã©ã§ãå ç«ç³»ã®å£åãç®æããŠããã®ã§ããèšãæããã°ãã³ããã19泚å°ã¯æ°ãã圢ã®åŸå€©æ§å ç«äžå šçå矀ãåŒãèµ·ããã®ã§ãããããŠç§ãã¡ã¯ããã蚌æããããšãã§ããŸã...
ã³ããã19ã¯ã¯ãã³ãèªç¶å ç«ç³»ã«æ·±å»ãªãã¡ãŒãžãäžããäºå®äžåŸå€©æ§å ç«äžå šçå矀ãåŒãèµ·ãããšããçµè«ã«è³ãã«ã¯ãæ¿åºã®å ¬åŒããŒã¿ã«ããã°ãã¯ã¯ãã³æ¥çš®è ãã¯ã¯ãã³éæ¥çš®è ãããã³ããã19ã«ææã»äŒæãã確çãé«ããšããçç±ãçè§£ãããå¿ èŠãããã
ãŸããåœå±ããããŒã¿ã瀺ãããã«ã¯ã¯ãã³æ¥çš®è ã®ç¶æ³ãé±ããšã«æªåããŠããããšã«æ°ã¥ããšãçããããéœåãããããŒã¿ã®å ¬è¡šãå®å šã«äžæ¢ããããšãå ¬å ±ã®å©çã«ãªããšå€æããããšãçè§£ããå¿ èŠãããã
以äžã®è¡šã¯ã第3é±ã第7é±ã第13é±ã®è±åœå¥åº·å®å šå±ã¯ã¯ãã³ç£èŠå ±åæžã«ããçäŸç衚ããã€ãªãåããããã®ã§ããã


äžèšã¯ã3ã¶æã®éã«ãããã幎霢局ã®ã¯ã¯ãã³æªæ¥çš®è ã®æ£è çºççãæ¥éã«æ¹åãã3ã¶æã®éã«ãããã幎霢局ã®3åæ¥çš®è ã®10äžäººåœããã®æ£è çºççãæãããäžæããããšã瀺ããŠããã
å®éã䞡矀ã®å·®ã¯éåžžã«å€§ããã2022幎ã®12é±ç®ã«ã¯ãå®éã®ã¯ã¯ãã³å¹æã¯60æ³ãã69æ³ã®éã§ãã€ãã¹391ïŒ ãšããäœãã§ããããšã蚌æããããããã¯ã2022幎2é±ç®ãŸã§ã«åã幎霢局ã§ãã€ãã¹104.7%ãšããããã§ã«æ°ã«ãªã广ããäœäžããŠããã

ãããã絶察ã«ã¯ã£ãããããŠããããããšããããŸãããã¹ã¡ãã£ã¢ã®ãã£ã³ããŒã³ã§ã¯ã广ãäœäžããŠãããããå ç«åãé«ãããããã«ããŒã¹ã¿ãŒãåããããšãå¿ é ã§ãããšä¿¡ããããŠããŸãããå®éã«ã¯ãCovid-19泚å°ã«é¢ããŠã¯ã¯ã¯ãã³ã®å¹æãäœäžããããšã¯ããåŸãŸããã
Covid-19ã¯ã¯ãã³ã¯ãmRNAãäœå ã«æ³šå ¥ããããã现èã«äŸµå ¥ããŠãSARS-CoV-2ãŠã€ã«ã¹ã«èŠãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœãããã«æç€ºããããšã§å¹æãçºæ®ãããšèããããŠããŸããäœå ã§äœçŸäžãã®ã¹ãã€ã¯ã»ãããã€ã³ãäœããããšãå ç«ã·ã¹ãã ãåããŠã¹ãã€ã¯ã»ãããã€ã³ãäœå€ã«æåºããå®éã®SARS-CoV-2ãŠã€ã«ã¹ãšééãããšãã«ã¯ãåãæäœãæŸåºããããšã«ãªã£ãŠããã®ã§ããã

ã§ããããåœå±ããã¯ã¯ãã³ã®å¹æã¯æéãšãšãã«åŒ±ãŸãããšè¿°ã¹ããšãããã®æ¬åœã®æå³ã¯ããå ç«ã·ã¹ãã ã®æ§èœãæéãšãšãã«åŒ±ãŸãããšããããšãªã®ã§ãã
çŸå®ã®ããŒã¿ã§èŠãããåé¡ã¯ãå ç«ã·ã¹ãã ãã¯ã¯ãã³æªæ¥çš®è ã®å€ãã«èŠããããããªèªç¶ãªç¶æ ã«æ»ã£ãŠããªãããšã§ããããããã§ããã°ãã¯ã¯ãã³å¹æã¯0%ã«è¿ããªã£ãŠããã¯ãã§ããã€ãã¹391%ãšããè¡æçãªæ°åã«ã¯ãªããªãã
13é±ç®ã®UKHSAã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã¯ãã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19çäŸãå ¥é¢ãæ»äº¡ã®ããŒã¿ãå«ãæçµå ±åæžã§ãã£ããUKHSAã¯ãè±åœæ¿åºã4æ1æ¥ããCovid-19ã®ç¡æé壿€æ»ãçµäºããããšã決å®ãããããšäž»åŒµããŠããã
ããããå®éã«ã¯ã3皮混åã¯ã¯ãã³æ¥çš®è ã®æãããçäŸæ°ãå®å šæ¥çš®è ã®æãããå ¥é¢æ°ãšæ»äº¡æ°ã®ããã§ããããšæ³åãããã
以äžã®å³ã¯ã22幎2æ28æ¥ãã3æ27æ¥ãŸã§ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19å ¥é¢çã§ãããã¯ã¯ãã³æªæ¥çš®ã®æ£è çã¯ãUKHSA Vaccine Surveillance Report - Week 13 - 2022ã®45ããŒãžããåŒçšãã2åæ¥çš®ã®æ£è çã¯ãåã¬ããŒãã®41ããŒãžã«èšèŒãããŠããå ¥é¢æ£è æ°ããç®åºããŸããã

10äžäººãããã®çºççã¯ã18-29æ³ãé€ããã¹ãŠã®å¹Žéœ¢å±€ã§ãå®å šæ¥çš®è ãæãé«ãã£ãã®ã§ãããã®ããŒã¿ã¯ã30æ³ä»¥äžã®ãã¹ãŠã®äºéã¯ã¯ãã³æ¥çš®è ããã¯ã¯ãã³æªæ¥çš®è ãããCovid-19ã§å ¥é¢ãã確çãé«ãããšã蚌æãããã®ã§ãã£ãã
以äžã®ã°ã©ãã¯ã22幎2æ28æ¥ãã3æ27æ¥ãŸã§ã®ã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19æ»äº¡çã§ããã¯ã¯ãã³æªæ¥çš®è çã¯UKHSA Vaccine Surveillance Report - Week 13 - 2022ã®45ããŒãžããåŒçšããããã«ã¯ã¯ãã³æ¥çš®è çã¯åã¬ããŒãã®44ããŒãžã«èšèŒãããŠããæ»äº¡è æ°ãçšããŠç®åºããã

10äžäººåœããã®æ»äº¡çã¯ãã¯ã¯ãã³æªæ¥çš®è ãšåãæ»äº¡çã®30-39æ³ãæ»äº¡çã®äœã18-29æ³ãé€ããã¹ãŠã®å¹Žéœ¢å±€ã§ãå®å šæ¥çš®è ãæãé«ãããšãããã£ãããã®ããŒã¿ããã40æ³ä»¥äžã®ããã«ã¯ã¯ãã³æ¥çš®è ã¯ãã¯ã¯ãã³æªæ¥çš®è ã«æ¯ã¹ãŠCovid-19ã§æ»äº¡ãã確çãé«ãããšã蚌æãããã
ãããã5ææ«ã«ãªããè±åœåœå®¶çµ±èšå±ãçºè¡šããããŒã¿ãèŠããšã10äžäººåœããã®æ»äº¡çã¯ããã¹ãŠã®å¹Žéœ¢å±€ã§ã¯ã¯ãã³æªæ¥çš®è ãæãäœããªã£ãŠããããšã確èªã§ããã
以äžã®ã°ã©ãã¯ã2022幎1æãã5æãŸã§ã®ã€ã³ã°ã©ã³ãã«ãããéã³ãã19ã®æ»äº¡ã«ã€ããŠãå幎霢局ã«ãããã¯ã¯ãã³æ¥çš®ã®æç¡ã«ããå¹Žéœ¢æšæºåæ»äº¡çã瀺ããŠããïŒæ°åã¯æè¿çºè¡šãããããŒã¿ã»ããã®è¡š2åç §ïŒã

ããã¯å¹Žéœ¢ã§æšæºåããæ°åã§ããã10äžäººåœããã®æ»äº¡çãã¯ã¯ãã³æªæ¥çš®è ã®éã§æãäœããšããäºå®ã¯ãã³ãã19ã®æ³šå°ã人ã ãæ®ºããŠãããããã被æ¥çš®è ã«åŸå€©æ§å ç«äžå šçå矀ãçºçãããŠãããšãã以å€ã«ãçµè«ã¯ãªãã®ã§ããã
ããããå ç«ã·ã¹ãã ã®æ·±å»ãªå£åãšåŸå€©æ§å ç«äžå šçåçŸ€ã®æ°ãã圢æ ã瀺ã蚌æ ãããäžæ¹ã§ããããåŒãèµ·ãããŠããæ£ç¢ºãªããã»ã¹ã«ã¯ãŸã çãããªãã®ã§ããã
äžã€ã®å¯èœæ§ãšããŠã以äžã®ãããªã·ããªãªãèããããã
ã¡ãã»ã³ãžã£ãŒãªãæ žé žïŒmRNAïŒã¯ãéºäŒåã®é åã«å¯Ÿå¿ããRNAã®äžæ¬éååã§ãã¿ã³ãã¯è³ªãåæããéçšã§ãªããœãŒã ã«ãã£ãŠèªã¿åãããã
ã³ããã19泚å°ã«ã¯ãäœå ã®çްèã«äŸµå ¥ããSARS-CoV-2ãŠã€ã«ã¹ãšãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœãããæç€ºããmRNAãå«ãŸããŠããŸãããããŠããã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœçŸäžåãšçްèããæŸåºãããå ç«ç³»ã¯ããããŠã€ã«ã¹ïŒç°ç©ãšèªèããäœãæ»æãåããŠãããšèãããšãããã®ã§ããã
ãããŠãã¹ãã€ã¯èçœãšæŠããæäœãäœã£ãŠã殺ãããåã³ã¹ãã€ã¯èçœïŒSARS-CoV-2ãŠã€ã«ã¹ã«ééããŠããããããããšãèšæ¶ããŠããã
ãããããã®ããã»ã¹ãçµãããªããšãããã©ãã ããïŒäœå ã«æ³šå ¥ãããmRNAãåžžã«çްèã«äŸµå ¥ããäœçŸäžãã®ã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªãäœãããã«æç€ºããŠãããšãããã©ãã ããïŒ
åœå±ã¯ã³ãã19ã¯ã¯ãã³ã¯æ³šå°éšäœã«æ®ããšäž»åŒµããããããã圌ãã¯åãã€ããç§åŠã¯ããã§ãªãããšã蚌æããŠããã
ãã¡ã€ã¶ãŒç€Ÿã«ä»£ãã£ãŠè¡ãããç ç©¶ã«ããã°ãããã¯å®éã«äœå ã®ããããèåšã«èç©ããããšã®ããšã§ããã

ãã®ç ç©¶ã®åé¡ç¹ã¯ã48æéåŸã«èç©ã芳å¯ããã®ããããããšã§ããã§ã¯ããã®èç©ãå ã«æ»ããã©ããã誰ãã©ããã£ãŠç¥ãããšãã§ããã®ã§ããããïŒæ°ã¶æããããã¯æ°å¹Žéãèç©ãããªããšã©ãããŠãããã®ã ããïŒããã§ãªãããšã蚌æããããŸã§ã¯ãæšæž¬ã«éããªãã
ãããäœå ã«æ³šå ¥ãããmRNAãåžžã«çްèã«äŸµå ¥ããé·æéã«ããã£ãŠäœçŸäžãã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœãããã«æç€ºããã®ã§ããã°ãããã¯å ç«ã·ã¹ãã ããããªããã°ãªããªãããäžã€ã®æåžžçãªããšã§ãããšèšããã§ãããããããããã®åŸãããŒã¹ã¿ãŒæ³šå°ãåããããã«èšãããããã«4åç®ã®æ³šå°ãåããããšã«ãªããŸãããããšãäœã¯ããã«äœçŸäžãã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœãåºããå ç«ã·ã¹ãã ãããã«é ·äœ¿ããããšã«ãªããŸãã
äœãäœçŸäžãã®ã¹ãã€ã¯ã»ãããã€ã³ãšã®æŠãã«å¿æ®ºãããäžæ¹ã§ãä»ã®æ¥åèŠææãç现èãæéããããšãã§ããªããªããããã¯ãHIVã§èµ·ããããšãšäŒŒãŠãããHIVã¯å ç«ç³»çްèã«ææããŠç Žå£ããä»ã®ç æ°ãæéããã®ãé£ããããŸãã
HIVãå ç«ç³»ãèããäœäžãããå ŽåãåŸå€©æ§å ç«äžå šçå矀ã«ã€ãªããå¯èœæ§ããããŸããããããHIVã«ææããäººãæ®ºãã®ã¯HIVãŠã€ã«ã¹ã§ã¯ãªããå ç«ã·ã¹ãã ããã¯ãæéã§ããªãæ¥åèŠææçãçãªã®ã§ãã
ã§ãããããã®çè«ãªããæ¿åºã®å ¬åŒããŒã¿ã«ãããšã3皮混åã¯ã¯ãã³ãæ¥çš®ãã人ã¯ãæªæ¥çš®ã®äººã«æ¯ã¹ãŠã³ãã19ã«ææãããããã³ãã19ãåªä»ããå¯èœæ§ãé«ããšããçç±ãå®å šã«çè§£ã§ããŸãã
å®å šãªã¯ã¯ãã³æ¥çš®è ãã¯ã¯ãã³éæ¥çš®è ãããã³ãã19ã§å ¥é¢ãããæ»äº¡ãããããå¯èœæ§ãé«ãçç±ãå®ç§ã«çè§£ã§ããã ããã
ãããŠãå¹Žéœ¢æšæºåãã10äžäººåœããã®æ»äº¡çãããã¹ãŠã®å¹Žéœ¢å±€ã§ã¯ã¯ãã³æªæ¥çš®è ã®éã§æãäœãçç±ãå®ç§ã«çè§£ã§ããã ããã